background image

Paid Clinical Trials Aberdeen

Discover 9 paid clinical trials in Aberdeen, South Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Avera Cancer Sequencing and Analytics Protocol (ASAP)

for
Cancer, Cancer Diagnosis, Early Detection of Cancer,
Location: 2 recruiting locations
Sponsor: Avera McKennan Hospital & University Health Center

Sex: All

Age: 18+

Code: NCT05142033

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non Small Cell Lung Cancer
Location: 48 recruiting locations
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT04928846

Phase3, Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

for
Breast Cancer, Early Breast Cancer
Location: 6 recruiting locations
Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT05774951

Phase3, Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

for
Plasma Cell Myeloma
Location: 283 recruiting locations
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 0+

Code: NCT05561387

Phase3, Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: 355 recruiting locations
Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06580314

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for
Pancreatic Acinar Cell Carcinoma,
Location: 200 recruiting locations
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04858334

Phase2, Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer,
Location: 70 recruiting locations
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06065748

Phase3, Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

for
Breast Cancer, Early Breast Cancer
Location: 121 recruiting locations
Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT05952557

Phase3, Recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

for
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma,
Location: 276 recruiting locations
Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05256225

Phase3, Recruiting